USO 24168

EMN30/64007957MMY3003 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation” (MajesTEC-4)

Disease Types: Multiple Myeloma

Eligibility Requirements:

• Subject must have a new diagnosis of symptomatic MM
• Subjects must have received 4 to 6 cycles of 3- or 4-drug induction therapy
that includes a PI and/or an IMiD with or without an anti-CD38 mAb and a
single or tandem ASCT
• Must have received high-dose chemotherapy and ASCT within 12
months of the start of induction therapy & be within 6 months of the
last ASCT
• Subject must have received only 1 LOT and achieved at least PR
• ECOG ≤2
• Subjects must not have received any maintenance therapy
• Subjects that have received any previous therapy with a gene modified
adoptive cell therapy are excluded
• Subjects with a history of allogeneic stem cell transplantation or prior organ
transplant are excluded

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg